Skip to content
★ Sign in to follow
Shanghai Haoyuan Chemexpress Co., Ltd. logo

Shanghai Haoyuan Chemexpress Co., Ltd. Stock: price and insider trades · China

皓元医药

CN·Mcap CN¥17.6BHealth Care

No insider purchase over the last 90 days. The latest, by 周治国, was filed 06 Apr 2023.

Shanghai Haoyuan Chemexpress Co., Ltd.: what insiders have been doing

Shanghai Haoyuan Chemexpress Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). The last twelve months, up to 5 November 2026, brought 5 filings signed by 2 insiders.

Only sales appear on the open market, 5 sales in all totalling €567k, filed by 2 insiders. One trade stands out by size: a sale of €198k from 李硕梁, disclosed on 11 December 2025.

Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. This delay matters because a trade only becomes useful information once it is public. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

Across the 514 companies tracked on its exchange, the median is 2 filings; at 5 filings, this issuer sits above that mark. Our records for Shanghai Haoyuan Chemexpress Co., Ltd. go back to 2023, with 1 purchase and 8 sales on the open market in total.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
9
Thresholds
n/a
Buy Volume
€109,271
1 ops. · all time
Sell Volume
€789,452
8 ops. · all time

Who traded when

BuySale
李硕梁4 sales
周治国1 sale
梅魁1 sale

Since the insiders bought

  • Filed 06 Apr 2023 · 1312 days ago · €109k
    -61.0%
    Entry CN¥58.80 · Close at T+365 CN¥22.96

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 17,810 of 26,912 companies
41.0
score / 100
Value
29
Quality
53
FCF yld0.5%
Earn yld1.4%
EV/EBITDA39.7x
ROE7.7%
Gross mgn47%
Net mgn8.3%
Debt/EBITDA4.5x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥82.62
Analyst consensus
2 analysts
1.33/5
CN¥95.00Target CN¥106.00(+28%)CN¥117.00
Income statement
RevenueCN¥2.9B
Gross profitCN¥1.4B47% margin
EBITDACN¥500.4M17% margin
Net incomeCN¥239.8M8.1% margin
Valuation
PER (trailing)68.3x
PER (forward)38.4x
P/Book5.3x
Beta0.66
Balance sheet & cash
Market capCN¥17.6B
Total debtCN¥2.2B
Free Cash FlowCN¥96M
Debt / Equity72%
Profitability & ownership
ROE7.7%
ROA4.1%
% insiders45.5%
% institutions11.0%
Last declaration on 25 June 2026
Declarations9 total
  • ▼
    核心技术人员Executives
    720,305 CNY16SSE
    7,812 shares@ CN¥711.332319.6% of flowA股XSHGSSE:273000000765915940
  • ▼
    核心技术人员Executives
    885,097 CNY16SSE
    9,588 shares@ CN¥711.672224.1% of flowA股XSHGSSE:273000000761621250
  • ▼
    核心技术人员Executives
    694,600 CNY22SSE
    7,550 shares@ CN¥709.2592100.0% of flowA股XSHGSSE:273000000761621200
  • ▼
    核心技术人员Executives
    2M CNY6SSE
    22,000 shares41.5% of flowA股XSHGSSE:273000000018963740
  • ▼
    核心技术人员Executives
    578,760 CNY3SSE
    8,000 shares14.8% of flowA股XSHGSSE:273000000016265150
  • ▼
    核心技术人员Executives
    383,292 CNY3SSE
    6,480 shares13.8% of flowA股XSHGSSE:173000009395574000
  • ▼
    核心技术人员Executives
    449,512 CNY4SSE
    12,880 shares17.6% of flowA股XSHGSSE:173000008169169200
  • ▼
    核心技术人员Executives
    900,303 CNY6SSE
    7,620 shares35.7% of flowA股XSHGSSE:173000006651822720
  • ▲
    核心技术人员Executives
    821,687 CNY5SSE
    7,620 shares32.9% of flowA股XSHGSSE:173000006651822620
    Canonical exit: 5 Jul 2023 (T+90)

9 of 9 declarations

About Shanghai Haoyuan Chemexpress Co., Ltd.

皓元医药 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative drugs.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations